Wound-healing modulation in upper airway stenosis-myths and facts

Head and Neck

Volumn 31, Issue 1, 2009, Pages 111-126

  Hirshoren, Nir ^a   Eliashar, Ron ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Airway stenosis; Larynx; Scar; Subglottic stenosis; Wound healing

Indexed keywords

3 AMINOPROPIONITRILE; ACETYLCYSTEINE; ANNTIREFLUX AGENT; ANTIBIOTIC AGENT; ANTIFIBROTIC AGENT; BLEOMYCIN; CEFALEXIN; COLCHICINE; DEXAMETHASONE; DROSTERPTOMYCIN; FLUOROURACIL; FLUOROURACIL TRIAMCINOLONE CONJUGATE; GASTROINTESTINAL AGENT; HALOFUGINONE; INTERLEUKIN 1BETA; METHYLPREDNISOLONE ACETATE; MITOMYCIN; PENICILLAMINE; PLACEBO; POTASSIUM PHENOXYMETHYL PENICILLIN; PREDNISONE; PROCAINE PENICILLIN; PROSTAGLANDIN E2; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TRANSFORMING GROWTH FACTOR BETA3; TRIAMCINOLONE DIACETATE; UNCLASSIFIED DRUG;

ADD ON THERAPY; ADJUVANT THERAPY; AIRWAY OBSTRUCTION; CELL MATURATION; CELL PROLIFERATION; CHONDROPATHY; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL TRIAL; CROSS LINKING; DISEASE COURSE; DRUG CONJUGATION; DRUG EFFECT; DRUG MECHANISM; ESOPHAGUS STRICTURE; FIBROSING ALVEOLITIS; FIBROSIS; GENE THERAPY; GLOMERULONEPHRITIS; HUMAN; HYPERBARIC OXYGEN; INFLAMMATION; INJECTION SITE NECROSIS; LARYNX STENOSIS; LEUKOPENIA; LIVER CIRRHOSIS; LUNG FIBROSIS; MYCOSIS; NEPHROBLASTOMA; NONHUMAN; OXYGEN BREATHING; PRIORITY JOURNAL; PROSTATE CARCINOMA; RESPIRATORY TRACT INJURY; REVIEW; SINGLE DRUG DOSE; SQUAMOUS CELL METAPLASIA; SUBGLOTTIC STENOSIS; SYSTEMIC SCLEROSIS; THROMBOCYTOPENIA; TRACHEA STENOSIS; TREATMENT DURATION; UPPER RESPIRATORY TRACT; URETHRA STRICTURE; VOCAL CORD DISORDER; WEGENER GRANULOMATOSIS; WOUND HEALING;

ACETYLCYSTEINE; AMINOPROPIONITRILE; ANIMALS; ANTIMETABOLITES; COLCHICINE; FLUOROURACIL; HUMANS; HYPERBARIC OXYGENATION; LARYNGOSTENOSIS; MITOMYCIN; NUCLEIC ACID SYNTHESIS INHIBITORS; PIPERIDINES; PROTEIN SYNTHESIS INHIBITORS; QUINAZOLINONES; RECURRENCE; WOUND HEALING;

EID: 58149494805     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.20925     Document Type: Review

References (158)

1. Lama PJ, Fechtner RD. Antifibrotics and wound healing in glaucoma surgery. Surv Ophthalmol 2003;48: 314-346.
2. Broughton G II, Janis JE, Attinger CE. The basic science of wound healing. Plast Reconstr Surg 2006; 117(7, Suppl):12S-34S.
3. Schilling Ja. Wound healing. Surg Clin North Am 1976;56:859-874.
4. Witte MB, Barbul A. General principles of wound healing. Surg Clin North Am 1997;77:509-528.
5. Kurkinen M, Vaheri A, Roberts PJ, Stenman S. Sequential appearance of fibronectin and collagen in experimental granulation tissue. Lab Invest 1980;43:47-51.
6. Pohlman TH, Stanness KA, Beatty PG, Ochs HD, Har-lan JM. An endothelial cell surface factor(s) induced in vitro by lipopolysaccharide, interleukin 1, and tumor necrosis factor-alpha increases neutrophil adherence by a CDw18-dependent mechanism. J Immunol 1986; 136:4548-4553.
7. Bevilacqua MP, Pober JS, Wheeler ME, Cotran RS, Gimbrone MA Jr. Interleukin 1 acts on cultured human vascular endothelium to increase the adhesion of polymorphonuclear leukocytes, monocytes, and related leukocyte cell lines. J Clin Invest 1985;76: 2003-2011.
8. Deming MV, Oech SR. Steroid and antihistaminic therapy for post intubation subglottic edema in infants and children. Anesthesiology 1961;22:933-936.
9. Biller HF, Harvey JE, Bone RC, Ogura JH. Laryngeal edema. An experimental study. Ann Otol Rhinol Laryn-gol 1970;79:1084-1087.
10. Kryzer TC Jr, Gonzalez C, Burgess LP. Effects of aerosolized dexamethasone on acute subglottic injury. Ann Otol Rhinol Laryngol 1992;101:95-99.
11. Postma DS, Prazma J, Woods CI, Sidman J, Pillsbury HC. Use of steroids and a long-acting vasoconstrictor in the treatment of postintubation croup. A ferret model. Arch Otolaryngol Head Neck Surg 1987;113: 844-849.
12. Darmon JY, Rauss A, Dreyfuss D, et al. Evaluation of risk factors for laryngeal edema after tracheal extuba-tion in adults and its prevention by dexamethasone. A placebo-controlled, double-blind, multicenter study. An-esthesiology 1992;77:245-251.
13. Ashcraft KW, Holder TM. The experimental treatment of esophageal strictures by intralesional steroid injections. J Thorac Cardiovasc Surg 1969;58:685-691.
14. Bonchek LI. Successful treatment of postintubation subglottic stenosis with intralesional steroid injections. Ann Thorac Surg 1973;15:84-87.
15. Cobb WB, Sudderth JF. Intralesional steroids in laryn-geal stenosis. A preliminary report. Arch Otolaryngol 1972;96:52-56.
16. Gnanapragasam A. Intralesional steroids in conservative management of subglottic stenosis of the larynx. Int Surg 1979;64:63-67.
17. Hoffman GS, Thomas-Golbanov CK, Chan J, Akst LM, Eliachar I. Treatment of subglottic stenosis, due to Wegener's granulomatosis, with intralesional corticosteroids and dilation. J Rheumatol 2003;30:1017-1021.
18. Croft CB, Zub K, Borowiecki B. Therapy of iatrogenic subglottic stenosis: a steroid/antibiotic regimen. Laryngoscope 1979;89:482-489.
19. Strome M, Ferguson CF. Multiple postintubation complications. Ann Otol Rhinol Laryngol 1974;83:432-438.
20. Sasaki CT, Horiuchi M, Koss N. Tracheostomy-related subglottic stenosis: bacteriologic pathogenesis. Laryngoscope 1979;89(6 Part 1):857-865.
21. Healy GB. An experimental model for the endoscopic correction of subglottic stenosis with clinical applications. Laryngoscope 1982;92(10 Part 1):1103-1115.
22. Supance JS. Antibiotics and steroids in the treatment of acquired subglottic stenosis. A canine model study. Ann Otol Rhinol Laryngol 1983;92(4, Part 1):377-382.
23. Campbell BH, Dennison BF, Durkin GE, Strigenz MA, Toohill RJ. Early and late dilatation for acquired sub-glottic stenosis. Otolaryngol Head Neck Surg 1986;95: 566-573.
24. Kil HK, Alberts MK, Liggitt HD, Bishop MJ. Dexa-methasone treatment does not ameliorate subglottic is-chemic injury in rabbits. Chest 1997;111:1356-1360.
25. Doolin EJ, Tsuno K, Strande LF, Santos MC. Pharma-cologic inhibition of collagen in an experimental model of subglottic stenosis. Ann Otol Rhinol Laryngol 1998; 107:275-279.
26. Perepelitsyn I, Shapshay SM. Endoscopic treatment of laryngeal and tracheal stenosis-has mitomycin C improved the outcome? Otolaryngol Head Neck Surg 2004;131:16-20.
27. Grim PS, Gottlieb LJ, Boddie A, Batson E. Hyperbaric oxygen therapy. JAMA 1990;263:2216-2220.
28. Al-Waili NS, Butler GJ. Effects of hyperbaric oxygen on inflammatory response to wound and trauma: possible mechanism of action. Sci World J 20063;6:425-441.
29. Gungor A, Poyrazoglu E, Cincik H, Sali M, Candan H, Ay H. The effectiveness of hyperbaric oxygen treatment in tracheal reconstruction with auricular cartilage grafts (experimental study). Am J Otolaryngol 2003; 24:390-394.
30. Hata T, Hoshi T, Kanamori K, et al. Mitomycin, a new antibiotic from Streptomyces. I. J Antibiot (Tokyo) 1956; 9:141-146.
31. Tomasz M, Palom Y. The mitomycin bioreductive antitu-mor agents: cross-linking and alkylation of DNA as the molecular basis of their activity. Pharmacol Ther 1997;76:73-87.
32. Miyamura S, Shigeno N, Matsui M, Wakaki S, Uzu K. The biological studies on mitomycin I. Antibacterial activities of mitomycin derivatives. J Antibiot (Tokyo) 1967;20:72-76.
33. Oboshi S, Matsui M, Ishii S, Masago N, Wakaki S. Antitu-mor studies on mitomycin derivatives. II. Effect of solid tumor of sarcoma-180. Gann 1967;58:315-321.
34. Rahbar R, Jones DT, Nuss RC, et al. The role of mitomy-cin in the prevention and treatment of scar formation in the pediatric aerodigestive tract: friend or foe? Arch Oto-laryngol Head Neck Surg2002;128:401-406.
35. Yamamoto T, Varani J, Soong HK, Lichter PR. Effects of 5-fluorouracil and mitomycin C on cultured rabbit subconjunctival fibroblasts. Ophthalmology 1990;97:1204-1210.
36. Desmouliére A, Redard M, Darby I, Gabbiani G. Apopto-sis mediates the decrease in cellularity during the transition between granulation tissue and scar. Am J Pathol 1995;146:56-66.
37. Ribeiro Fde A, Guaraldo L, Borges Jde P, Zacchi FF, Eck-ley CA. Clinical and histological healing of surgical wounds treated with mitomycin C. Laryngoscope 2004; 114:148-152.
38. Gray SD, Tritle N, Li W. The effect of mitomycin on extracellular matrix proteins in a rat wound model. Laryngoscope 2003;113:237-242.
39. Kunitomo N, Mori S. Studies on the pterygium. Part IV. A treatment of the pterygium by mitomycin-c instillation. Acta Soc Ophthalmol 1963;67:610-617.
40. Caliskan S, Orhan M, Irkeç M. Intraoperative and postoperative use of mitomycin-C in the treatment of primary pterygium. Ophthalmic Surg Lasers 1996;27:600-604.
41. Chen CW, Huang HT, Bair JS, Lee CC. Trabeculectomy with simultaneous topical application of mitomycin-C in refractory glaucoma. J Ocul Pharmacol 1990;6:175-182.
42. Urban RC Jr, Kaufman LM. Mitomycin in the treatment of hypertrophic conjunctival scars after strabismus surgery. J Pediatr Ophthalmol Strabismus 1994;31:96-98.
43. O'Reilly RC, Goldman SA, Widner SA, Cass SP. Creating a stable tympanic membrane perforation using mitomy-cin C. Otolaryngol Head Neck Surg 2001;124:40-45.
44. D'ereditá R. Contact diode laser myringotomy and mito-mycin C in children. Otolaryngol Head Neck Surg 2004; 130:742-746.
45. Annino DJ Jr, Goguen LA. Mitomycin C for the treatment of pharyngoesophageal stricture after total laryng-opharyngectomy and microvascular free tissue reconstruction. Laryngoscope 2003;113:1499-1502.
46. Erard AC, Monnier P, Spiliopoulos A, Nicod L. Mitomy-cin C for control of recurrent bronchial stenosis: a case report. Chest 2001;120:2103-2105.
47. Chung JH, Cosenza MJ, Rahbar R, Metson RB. Mitomy-cin C for the prevention of adhesion formation after en-doscopic sinus surgery: a randomized, controlled study. Otolaryngol Head Neck Surg 2002;126:468-474.
48. Anand VK, Tabaee A, Kacker A, Newman JG, Huang C. The role of mitomycin C in preventing synechia and stenosis after endoscopic sinus surgery. Am J Rhinol 2004; 18:311-314.
49. Ingrams DR, Volk MS, Biesman BS, Pankratov MM, Shapshay SM. Sinus surgery: does mitomycin C reduce stenosis? Laryngoscope 1998;108:883-886.
50. Gillespie MB, Day TA, Sharma AK, Brodsky MB, Martin-Harris B. Role of mitomycin in upper digestive tract stricture. Head Neck 2007;29:12-17.
51. Jones LM, Guillory VL, Mair EA. Total nasopharyngeal stenosis: treatment with laser excision, nasopharyngeal obturators, and topical mitomycin-c. Otolaryngol Head Neck Surg 2005;133:795-798.
52. Afzal NA, Albert D, Thomas AL, Thomson M. A child with oesophageal strictures. Lancet 2002;359:1032.
53. Choong CK, Haddad FJ, Gee EY, Cooper JD. Feasibility and safety of airway bypass stent placement and influence of topical mitomycin C on stent patency. J Thorac Cardiovasc Surg 2005;129:632-638.
54. Eliashar R, Eliachar I, Esclamado R, Gramlich T, Strome M. Can topical mitomycin prevent laryngotra-cheal stenosis? Laryngoscope 1999;109:1594-1600.
55. Cincik H, Gungor A, Cakmak A, et al. The effects of mi-tomycin C and 5-fluorouracil/triamcinolone on fibrosis/scar tissue formation secondary to subglottic trauma (experimental study). Am J Otolaryngol 2005;26:45-50.
56. Hardillo J, Vanclooster C, Delaere PR. An investigation of airway wound healing using a novel in vivo model. Laryngoscope 2001;111:1174-1182.
57. Roh JL. Prevention of posterior glottic stenosis by mito-mycin C. Ann Otol Rhinol Laryngol 2005;114:558-562.
58. Spector JE, Werkhaven JA, Spector NC, et al. Preservation of function and histologic appearance in the injured glottis with topical mitomycin-C. Laryngoscope 1999; 109(7 Part 1):1125-1129.
59. Garrett CG, Soto J, Riddick J, Billante CR, Reinisch L. Effect of mitomycin-C on vocal fold healing in a canine model. Ann Otol Rhinol Laryngol 2001;110:25-30.
60. Roh JL, Kim DH, Rha KS, Sung MW, Kim KH, Park CI. Benefits and risks of mitomycin use in the traumatized tracheal mucosa. Otolaryngol Head Neck Surg 2007; 136:459-463.
61. Roh JL, Lee YW, Park CI. Can mitomycin C really prevent airway stenosis? Laryngoscope 2006;116:440-445.
62. Coppit G, Perkins J, Munaretto J, Nielsen R, McKinney L, Ulnick K. The effects of mitomycin-C and stenting on airway wound healing after laryngotracheal reconstruction in a pig model. Int J Pediatr Otorhinolaryngol 2000;53:125-135.
63. Correa AJ, Reinisch L, Sanders DL, et al. Inhibition of subglottic stenosis with mitomycin-C in the canine model. Ann Otol Rhinol Laryngol 1999;108(11 Part 1):1053-1060.
64. Eliashar R, Gross M, Maly B, Sichel JY. Mitomycin does not prevent laryngotracheal repeat stenosis after endo-scopic dilation surgery: an animal study. Laryngoscope 2004;114:743-746.
65. Shvidler J, Bothwell NE, Cable B. Refining indications for the use of mitomycin C using a randomized controlled trial with an animal model. Otolaryngol Head Neck Surg 2007;136:653-657.
66. Spector JE, Werkhaven JA, Spector NC, Huang S, Sanders D, Reinisch L. Prevention of anterior glottic resteno-sis in a canine model with topical mitomycin-C. Ann Otol Rhinol Laryngol 2001;110:1007-1010.
67. Roh JL, Yoon YH. Prevention of anterior glottic stenosis after bilateral vocal fold stripping with mitomycin C. Arch Otolaryngol Head Neck Surg 2005;131:690-695.
68. Ward RF, April MM. Mitomycin-C in the treatment of tracheal cicatrix after tracheal reconstruction. Int J Pediatr Otorhinolaryngol 1998;44:221-226.
69. Simpson CB, James JC. The efficacy of mitomycin-C in the treatment of laryngotracheal stenosis. Laryngoscope 2006;116:1923-1925.
70. Rahbar R, Shapshay SM, Healy GB. Mitomycin: effects on laryngeal and tracheal stenosis, benefits, and complications. Ann Otol Rhinol Laryngol 2001;110:1-6.
71. Ubell ML, Ettema SL, Toohill RJ, Simpson CB, Merati AL. Mitomycin-c application in airway stenosis surgery: analysis of safety and costs. Otolaryngol Head Neck Surg 2006;134:403-406.
72. Roh JL, Yoon YH. Prevention of anterior glottic stenosis after transoral microresection ofglottic lesions involving the anterior commissure with mitomycin C. Laryngoscope 2005;115:1055-1059.
73. Rahbar R, Valdez TA, Shapshay SM. Preliminary results of intraoperative mitomycin-C in the treatment and prevention of glottic and subglottic stenosis. J Voice 2000; 14:282-286.
74. Perepelitsyn I, Shapshay SM. Endoscopic treatment of laryngeal and tracheal stenosis - has mitomycin C improved the outcome? Otolaryngol Head Neck Surg 2004;131:16-20.
75. Hartnick CJ, Hartley BE, Lacy PD, et al. Topical mito-mycin application after laryngotracheal reconstruction: a randomized, double-blind, placebo-controlled trial. Arch Otolaryngol Head Neck Surg 2001;127:1260-1264.
76. Valdez TA, Shapshay SM. Idiopathic subglottic stenosis revisited. Ann Otol Rhinol Laryngol 2002;111:690-695.
77. Hueman EM, Simpson CB. Airway complications from topical mitomycin C. Otolaryngol Head Neck Surg 2005; 133:831-835.
78. Liebmann JM, Ritch R, Marmor M, Nunez J, Wolner B. Initial 5-fluorouracil trabeculectomy in uncomplicated glaucoma. Ophthalmology 1991;98:1036-1041.
79. Smith S, D'Amore PA, Dreyer EB. Comparative toxicity of mitomycin C and 5-fluorouracil in vitro. Am J Oph-thalmol 1994;118:332-337.
80. Ingrams DR, Sukin SW, Ashton P, Valtonen HJ, Pankra-tov MM, Shapshay SM. Does slow-release 5-fluorouracil and triamcinolone reduce subglottic stenosis? Otolaryn-gol Head Neck Surg 1998;118:174-177.
81. Ingrams DR, Ashton P, Dhingra J, Shah R, Shapshay SM. Slow-release 5-fluorouracil and triamcinolone reduces subglottic stenosis in a rabbit model. Ann Otol Rhinol Laryngol 2000;109:422-424.
82. Kivirikko KI. Collagens and their abnormalities in a wide spectrum of diseases. Ann Med 1993;25:113-126.
83. Prockop DJ, Kivirikko KI. Collagens: molecular biology, diseases, and potentials for therapy. Ann Rev Biochem 1995;64:403-434.
84. Kinabo LD, McKellar QA. Pharmacokinetics of halofugi-none in cattle. Br Vet J 1989;145:546-551.
85. Xavier S, Piek E, Fujii M, et al. Amelioration of radiation-induced fibrosis: inhibition of transforming growth factor-beta signaling by halofuginone. J Biol Chem 2004;279:15167-15176.
86. McGaha TL, Phelps RG, Spiera H, Bona C. Halofugi-none, an inhibitor of type-I collagen synthesis and skin sclerosis, blocks transforming-growth-factor- beta-medi-ated Smad3 activation in fibroblasts. J Invest Dermatol 2002;118:461-470.
87. Elkin M, Reich R, Nagler A, et al. Inhibition of matrix metalloproteinase-2 expression and bladder carcinoma metastasis by halofuginone. Clin Cancer Res 1999;5: 1982-1988.
88. Pines M, Snyder D, Yarkoni S, Nagler A. Halofuginone to treat fibrosis in chronic graft-versus-host disease and scle-roderma. Biol Blood Marrow Transplant 2003;9:417-425.
89. Levi-Schaffer F, Nagler A, Slavin S, Knopov V, Pines M. Inhibition of collagen synthesis and changes in skin morphology in murine graft-versus-host disease and tight skin mice: effect of halofuginone. J Invest Dermatol 1996;106:84-88.
90. Pines M, Knopov V, Genina O, Lavelin I, Nagler A. Halo-fuginone, a specific inhibitor of collagen type I synthesis, prevents dimethylnitrosamine- induced liver cirrhosis. J Hepatol 1997;27:391-398.
91. Nagler A, Firman N, Feferman R, Cotev S, Pines M, Shoshan S. Reduction in pulmonary fibrosis in vivo by halofuginone. Am J Respir Crit Care Med 1996;154(4 Part 1):1082-1086.
92. Nagler A, Rivkind AI, Raphael J, et al. Halofuginone-an inhibitor of collagen type I synthesis-prevents postoperative formation of abdominal adhesions. Ann Surg 1998;227:575-582.
93. Arbell D, Udassin R, Koplewitz BZ, et al. Prevention of esophageal strictures in a caustic burn model using halo-fuginone, an inhibitor of collagen type I synthesis. Laryngoscope 2005;115:1632-1635.
94. Ozçelik MF, Pekmezci S, Saribeyoglu K, Unal E, Gümüştaş K, Dogusoy G. The effect of halofuginone, a specific inhibitor of collagen type 1 synthesis, in the prevention of esophageal strictures related to caustic injury. Am J Surg 2004;187:257-260.
95. Benchetrit S, Yarkoni S, Rathaus M, et al. Halofuginone reduces the occurrence of renal fibrosis in 5/6 nephrec-tomized rats. Isr Med Assoc J 2007;9:30-34.
96. Sheffer Y, Leon O, Pinthus JH, et al. Inhibition of fibroblast to myofibroblast transition by halofuginone contributes to the chemotherapy- mediated antitumoral effect. Mol Cancer Ther 2007;6:570-577.
97. Olbrich KC, Meade R, Bruno W, Heller L, Klitzman B, Levin LS. Halofuginone inhibits collagen deposition in fibrous capsules around implants. Ann Plast Surg 2005; 54:293-296; discussion 296.
98. Jaidane M, Ali-El-Dein B, Ounaies A, Hafez AT, Mohsen T, Bazeed M. The use of halofuginone in limiting ure-thral stricture formation and recurrence: an experimental study in rabbits. J Urol 2003;170:2049-2052.
99. Eliashar R, Ochana M, Maly B, Pines M, Sichel JY, Nagler A. Halofuginone prevents subglottic stenosis in a canine model. Ann Otol Rhinol Laryngol 2006;115:382-386.
100. Ertugrul EE, Cincik H, Dogru S, et al. Effects of halofuginone on fibrosis formation secondary to experimentally induced subglottic trauma. Laryngoscope 2007;117: 299-302.
101. Hoffman DL, Owen JA, Chvapil M. Healing of skin incision wounds treated with topically applied BAPN free base in the rat. Exp Mol Pathol 1983;39:154-162.
102. Peacock EE, Madden JW. Administration of beta-amino-propionitrile to human beings with urethral strictures: a prelimary report. Am J Surg 1978;136:600-605.
103. Madden JW, Davis WM, Butler C II, Peacock EE Jr. Experimental esophageal lye burns. II. Correcting established strictures with beta-aminopropionitrile and bou-gienage. Ann Surg 1973;178:277-284.
104. Gehanno P, Guedon C. Inhibition of experimental esoph-ageal lye strictures by penicillamine. Arch Otolaryngol 1981;107:145-147.
105. Geever EF, Youssef S, Seifter E, Levenson SM. Penicill-amine and wound healing in young guinea pigs. J Surg Res 1967;7:160-166.
106. Koufman JA, Branch ME, Ryu JH. A comparison of the carbon dioxide and neodymium: YAG lasers in a canine model of acquired subglottic stenosis. J Otolaryngol 1988;17:223-226.
107. Liu AJ, Richardson MA. Effects of N-acetylcysteine on experimentally induced esophageal lye injury. Ann Otol Rhinol Laryngol 1985;94(5, Part 1):477-482.
108. Livingston GL, Schild JA. Lathyrogenic agents as therapy for subglottic stenosis - a pilot study. Otolaryngol Head Neck Surg 1987;97:446-451.
109. Koufman JA. The otolaryngologic manifestations of gastroesophageal reflux disease (GERD): a clinical investigation of 225 patients using ambulatory 24-hour pH monitoring and an experimental investigation of the role of acid and pepsin in the development of la-ryngeal injury. Laryngoscope 1991;101(4 Part 2, Suppl 53):1-78.
110. Bain WM, Harrington JW, Thomas LE, Schaefer SD. Head and neck manifestations of gastroesophageal reflux. Laryngoscope 1983;93:175-179.
111. Little FB, Koufman JA, Kohut RI, Marshall RB. Effect of gastric acid on the pathogenesis of subglottic stenosis. Ann Otol Rhinol Laryngol 1985;94:516-519.
112. Walner DL, Stern Y, Gerber ME, Rudolph C, Baldwin CY, Cotton RT. Gastroesophageal reflux in patients with subglottic stenosis. Arch Otolaryngol Head Neck Surg 1998;124:551-555.
113. Jindal JR, Milbrath MM, Shaker R, Hogan WJ, Toohill RJ. Gastroesophageal reflux disease as a likely cause of "idiopathic" subglottic stenosis. Ann Otol Rhinol Laryngol 1994;103:186-191.
114. Delahunty JE, Cherry J. Experimentally produced vocal cord granulomas. Laryngoscope 1968;78:1941-1947.
115. Yellon RF, Parameswaran M, Brandom BW. Decreasing morbidity following laryngotracheal reconstruction in children. Int J Pediatr Otorhinolaryngol 1997;41: 145-154.
116. Roh JL, Lee YW, Park HT. Effect of acid, pepsin, and bile acid on the stenotic progression of traumatized subglottis. Am J Gastroenterol 2006;101: 1186-1192.
117. Yellon RF, Szeremeta W, Grandis JR, Diguisseppe P, Dickman PS. Subglottic injury, gastric juice, corticoste-roids, and peptide growth factors in a porcine model. Laryngoscope 1998;108:854-862.
118. Adhami T, Goldblum JR, Richter JE, Vaezi MF. The role of gastric and duodenal agents in laryngeal injury: an experimental canine model. Am J Gastroenterol 2004;99:2098-2106.
119. Ford CN. Evaluation and management of laryngo-pha-ryngeal reflux. JAMA 2005;294:1534-1540.
120. Koufman J, Sataloff RT, Toohill R. Laryngopharyngeal reflux: consensus conference report. J Voice 1996;10: 215-216.
121. Karkos PD, Wilson JA. Empiric treatment of laryngo-pharyngeal reflux with proton pump inhibitors: a systematic review. Laryngoscope 2006;116:144-148.
122. Gray S, Miller R, Myer CM III, Cotton RT. Adjunctive measures for successful laryngotracheal reconstruction. Ann Otol Rhinol Laryngol 1987;96:509-513.
123. Zalzal GH, Choi SS, Patel KM. The effect of gastro-esophageal reflux on laryngotracheal reconstruction. Arch Otolaryngol Head Neck Surg 1996;122:297-300.
124. Riedel K, Riedel F, Goessler UR, Holle G, Germann G, Sauerbier M. Current status of genetic modulation of growth factors in wound repair. Int J Mol Med 2006; 17:183-193.
125. Eming SA, Krieg T, Davidson JM. Gene therapy and wound healing. Clin Dermatol 2007;25:79-92.
126. Branski RC, Rosen CA, Verdolini K, Hebda PA. Markers of wound healing in vocal fold secretions from patients with laryngeal pathology. Ann Otol Rhinol Laryngol 2004;113:23-29.
127. Branski RC, Rosen CA, Verdolini K, Hebda PA. Biochemical markers associated with acute vocal fold wound healing: a rabbit model. J Voice 2005;19:283-289.
128. Branski RC, Sandulache VC, Dohar JE, Hebda PA. Mu-cosal wound healing in a rabbit model of subglottic stenosis: biochemical analysis of secretions. Arch Otolaryn-gol Head Neck Surg 2005;131:153-157.
129. Sandulache VC, Chafin JB, Li-Korotky HS, Otteson TD, Dohar JE, Hebda PA. Elucidating the role of interleukin 1beta and prostaglandin E2 in upper airway mucosal wound healing. Arch Otolaryngol Head Neck Surg 2007;133:365-374.
130. Walner DL, Cotton RT, Willging JP, Bove KE, Toriumi DM. Model for evaluating the effect of growth factors on the larynx. Otolaryngol Head Neck Surg 1999;120: 78-83.
131. King JD, Stringer SP, Chegini N, Donnelly WH, Cassisi NJ, Schultz GS. TGF-alpha protein and receptor localization in laryngotracheal tissue. Otolaryngol Head Neck Surg 1993;109:915-925.
132. Yellon RF, Szeremeta W, Grandis JR, Diguisseppe P, Dickman PS. Subglottic injury, gastric juice, corticoste-roids, and peptide growth factors in a porcine model. Laryngoscope 1998;108:854-62.
133. Border WA, Okuda S, Languino LR, Sporn MB, Ruo-slahti E. Suppression of experimental glomerulonephri-tis by antiserum against transforming growth factor beta 1. Nature 1990;346:371-374.
134. Broekelmann TJ, Limper AH, Colby TV, McDonald JA. Transforming growth factor beta 1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis. Proc Natl Acad Sci U S A 1991;88:6642-6646.
135. Vignola AM, Chanez P, Chiappara G, et al. Transforming growth factor-beta expression in mucosal biopsies in asthma and chronic bronchitis. Am J Respir Crit Care Med 1997;156(2 Part 1):591-599.
136. Redington AE, Madden J, Frew AJ, et al. Transforming growth factor-beta 1 in asthma. Measurement in bron-choalveolar lavage fluid. Am J Respir Crit Care Med 1997;156(2 Part 1):642-647.
137. Sporn MB, Roberts AB, Wakefield LM, de Crombrugghe B. Some recent advances in the chemistry and biology of transforming growth factor-beta. J Cell Biol 1987;105: 1039-1045.
138. Shah M, Foreman DM, Ferguson MW. Neutralisation of TGF-beta 1 and TGF-beta 2 or exogenous addition of TGF-beta 3 to cutaneous rat wounds reduces scarring. J Cell Sci 1995;108 (Part 3):985-1002.
139. Loewen MS, Walner DL, Caldarelli DD. Improved airway healing using transforming growth factor beta-3 in a rabbit model. Wound Repair Regen 2001;9:44-49.
140. Scioscia KA, Miller F, April MM, Gruber BL. Growth factors in subglottic stenosis. Ann Otol Rhinol Laryngol 1996;105:936-943.
141. Walner DL, Heffelfinger SC, Stern Y, Abrams MJ, Miller MA, Cotton RT. Potential role of growth factors and extracellular matrix in wound healing after laryngotra-cheal reconstruction. Otolaryngol Head Neck Surg 2000;122:363-366.
142. Dillard DG, Gal AA, Roman-Rodriguez J, White S, Jacobs IN. Transforming growth factor and neutralizing antibodies in subglottic stenosis. Ann Otol Rhinol Lar-yngol 2001;110(5 Part 1):393-400.
143. Macauley SP, Schultz GS, Bruckner BA, Krawetz SA, Yang TP. Effects of transforming growth factor-beta1 on extracellular matrix gene expression by human fibro-blasts from a laryngeal stenotic lesion. Wound Repair Regen 1996;4:269-277.
144. Karagiannidis C, Velehorschi V, Obertrifter B, Macha HN, Linder A, Freitag L. High-level expression of matrix-associated transforming growth factor-beta1 in benign airway stenosis. Chest 2006;129:1298-1304.
145. Kumar RK, Herbert C, Kasper M. Reversibility of airway inflammation and remodelling following cessation of antigenic challenge in a model of chronic asthma. Clin Exp Allergy 2004;34:1796-1802.
146. Morishima Y, Nomura A, Uchida Y, et al. Triggering the induction of myofibroblast and fibrogenesis by airway epithelial shedding. Am J Respir Cell Mol Biol 2001; 24:1-11.
147. Cotton RT. Pediatric laryngotracheal stenosis. J Pediatr Surg 1984;19:699-704.
148. Lorenz RR. Adult laryngotracheal stenosis: etiology and surgical management. Curr Opin Otolaryngol Head Neck Surg 2003;11:467-472.
149. O'Neill JA Jr. Experience with iatrogenic laryngeal and tracheal stenoses. J Pediatr Surg 1984;19:235-238.
150. Herrington HC, Weber SM, Andersen PE. Modern management of laryngotracheal stenosis. Laryngoscope 2006;116:1553-1557.
151. Simpson GT, Strong MS, Healy GB, Shapshay SM, Vaughan CW. Predictive factors of success or failure in the endoscopic management of laryngeal and tracheal stenosis. Ann Otol Rhinol Laryngol 1982;91(4 Part 1):384-388.
152. Shapshay SM, Beamis JF Jr, Hybels RL, Bohigian RK. Endoscopic treatment ofsubglottic and tracheal stenosis by radial laser incision and dilation. Ann Otol Rhinol Laryngol 1987;96:661-664.
153. Giudice M, Piazza C, Foccoli P, Toninelli C, Cavaliere S, Peretti G. Idiopathic subglottic stenosis: management by endoscopic and open-neck surgery in a series of 30 patients. Eur Arch Otorhinolaryngol 2003;260:235-238.
154. Lano CF Jr, Duncavage JA, Reinisch L, Ossoff RH, Courey MS, Netterville JL. Laryngotracheal reconstruction in the adult: a ten year experience. Ann Otol Rhinol Laryngol 1998;107:92-97.
155. Hinder RA, Branton SA, Floch NR. Surgical therapy for supraesophageal reflux complications of gastroesophageal reflux disease. Am J Med 2000;108 (Suppl 4a): 178S-180S.
156. Steward DL, Wilson KM, Kelly DH, et al. Proton pump inhibitor therapy for chronic laryngo-pharyngitis: a randomized placebo-control trial. Otolaryngol Head Neck Surg 2004;131:342-350.
157. Williams RB, Szczesniak MM, Maclean JC, Brake HM, Cole IE, Cook IJ. Predictors of outcome in an open label, therapeutic trial of high-dose omeprazole in laryngitis. Am J Gastroenterol 2004;99:777-785.
158. Zalesska-Krecicka M, Krecicki T, Iwanczak B, Blitek A, Horobiowska M. Laryngeal manifestations of gastro-esophageal reflux disease in children. Acta Otolaryngol 2002;122:306-310.